Genetic Technologies Ltd (GENE)
2.335
-0.08
(-3.51%)
USD |
NASDAQ |
May 08, 11:35
Genetic Technologies Enterprise Value
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 07, 2024 | 8.125M |
| May 06, 2024 | 7.948M |
| May 03, 2024 | 7.396M |
| May 02, 2024 | 7.256M |
| May 01, 2024 | 7.860M |
| April 30, 2024 | 7.684M |
| April 29, 2024 | 7.640M |
| April 26, 2024 | 7.248M |
| April 25, 2024 | 7.067M |
| April 24, 2024 | 7.376M |
| April 23, 2024 | 7.992M |
| April 22, 2024 | 7.904M |
| April 19, 2024 | 6.385M |
| April 18, 2024 | 6.846M |
| April 17, 2024 | 9.616M |
| April 16, 2024 | 9.655M |
| April 15, 2024 | 10.04M |
| April 12, 2024 | 10.24M |
| April 11, 2024 | 9.770M |
| April 10, 2024 | 8.839M |
| April 09, 2024 | 8.539M |
| April 08, 2024 | 8.308M |
| April 05, 2024 | 8.154M |
| April 04, 2024 | 8.308M |
| April 03, 2024 | 8.193M |
| Date | Value |
|---|---|
| April 02, 2024 | 7.885M |
| April 01, 2024 | 8.385M |
| March 28, 2024 | 8.578M |
| March 27, 2024 | 8.270M |
| March 26, 2024 | 7.885M |
| March 25, 2024 | 7.308M |
| March 22, 2024 | 7.731M |
| March 21, 2024 | 7.077M |
| March 20, 2024 | 7.810M |
| March 19, 2024 | 7.847M |
| March 18, 2024 | 7.885M |
| March 15, 2024 | 7.808M |
| March 14, 2024 | 7.500M |
| March 13, 2024 | 7.385M |
| March 12, 2024 | 7.327M |
| March 11, 2024 | 7.710M |
| March 08, 2024 | 8.056M |
| March 07, 2024 | 8.116M |
| March 06, 2024 | 8.557M |
| March 05, 2024 | 7.368M |
| March 04, 2024 | 7.731M |
| March 01, 2024 | 6.423M |
| February 29, 2024 | 5.656M |
| February 28, 2024 | 5.038M |
| February 27, 2024 | 4.923M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
2.959M
Minimum
Dec 21 2023
78.44M
Maximum
Feb 17 2021
21.10M
Average
15.42M
Median
May 10 2023
Enterprise Value Benchmarks
| Alterity Therapeutics Ltd | -- |
| Kazia Therapeutics Ltd | 5.536M |
| Immutep Ltd | -- |
| Opthea Ltd | 119.24M |
| Mesoblast Ltd | -- |